About ANTENGENE-B Company

Deqi Pharmaceutical is a leading biopharmaceutical company focused on innovative anti-tumor drugs. Our uniqueness stems from our industry-leading R&D capabilities and a differentiated strategic approach to developing new anti-tumor therapies. Our vision is to discover, develop, and commercialize the world's first, unique, and/or best-in-class treatments to treat patients without borders and improve patients' living standards. Through effective use of resources and with outstanding capabilities and differentiated R&D strategies in target selection, Deqi Pharmaceutical has established a strong and highly collaborative R&D pipeline composed of 12 products, including 2 late-stage clinical assets and 4 early-stage clinical assets. Additionally, we are developing six pre-clinical development drugs that focus on innovative targets or mechanisms of action and have the potential to become first-in-class to address huge unmet medical needs. Furthermore, these drugs target key pathways of carcinogenesis and have the potential for joint application with each other. Since our establishment, we have established a solid R&D structure in the Asia-Pacific region, and have Pan-Asia Pacific clinical research and development capabilities. At this stage, we are establishing a commercialization team in the Asia-Pacific region to support the recent product launch. The commercialization team consists of multinational company leaders with rich commercial experience and senior practitioners with deep understanding of the dynamics of various local markets.